Bryce A Kerlin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3236680/publications.pdf

Version: 2024-02-01

		257450	214800
86	2,389	24	47
papers	citations	h-index	g-index

91	91	91	2630
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Drive-Through Anticoagulation Clinic During the COVID-19 Pandemic. Journal for Nurse Practitioners, 2022, 18, 92-96.	0.8	2
2	Safety and effectiveness of recombinant factor XIIIâ€A2 in congenital factor XIII deficiency: Realâ€world evidence. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12628.	2.3	3
3	Selective modulator of nuclear receptor PPARÎ³ with reduced adipogenic potential ameliorates experimental nephrotic syndrome. IScience, 2022, 25, 104001.	4.1	3
4	Moderate-intensity aerobic exercise vs desmopressin in adolescent males with mild hemophilia A: a randomized trial. Blood, 2022, 140, 1156-1166.	1.4	2
5	Proteaseâ€activated receptors: An illustrated review. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 17-26.	2.3	27
6	Bleeding Associated with Connective Tissue Disorders. , 2021, , 201-209.		0
7	Plasma Cytokine Profiling to Predict Steroid Resistance in Pediatric Nephrotic Syndrome. Kidney International Reports, 2021, 6, 785-795.	0.8	7
8	Nephrotic syndrome disease activity is proportional to its associated hypercoagulopathy. Thrombosis Research, 2021, 201, 50-59.	1.7	13
9	Use of electronic selfâ€administered bleeding assessment tool in diagnosis of paediatric bleeding disorders. Haemophilia, 2021, 27, 710-716.	2.1	3
10	A pilot randomized trial of atorvastatin as adjunct therapy in patients with acute venous thromboembolism. Blood Coagulation and Fibrinolysis, 2021, 32, 16-22.	1.0	5
11	Role of direct oral anticoagulants in patients withÂkidney disease. Kidney International, 2020, 97, 664-675.	5.2	35
12	Nephrotic syndromeâ€associated hypercoagulopathy is alleviated by both pioglitazone and glucocorticoid which target two different nuclear receptors. Physiological Reports, 2020, 8, e14515.	1.7	7
13	Recognition and Care of a Newborn with FXIII Deficiency. , 2020, , 71-80.		0
14	A Novel Assay Using Enzyme Capture - ELISA for Accurate Determination of Factor XIII Activity. Blood, 2020, 136, 23-24.	1.4	0
15	Direct Oral Anticoagulants Reduce Hypercoagulopathy and Preserve Podocyte Function in an Experimental Model of Glomerular Disease. Blood, 2020, 136, 26-26.	1.4	0
16	Venous thromboembolism in chronic pediatric heart disease is associated with substantial health care burden and expenditures. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 372-382.	2.3	2
17	Inpatient Health Care Utilization in Children With Hemophilia Before and After the Joint Outcome Study Publication. Journal of Pediatric Hematology/Oncology, 2019, 41, e284-e289.	0.6	2
18	Association of infections and venous thromboembolism in hospitalized children with nephrotic syndrome. Pediatric Nephrology, 2019, 34, 261-267.	1.7	29

#	Article	IF	Citations
19	Variation in Platelet Delta Granules Over Time in Young Women Undergoing Evaluation for Heavy Menstrual Bleeding. Pediatric and Developmental Pathology, 2019, 22, 123-127.	1.0	1
20	Treatment-Related Outcomes in Pagetâ€“Schroetter Syndromeâ€”A Cross-Sectional Investigation. Journal of Pediatrics, 2019, 207, 226-232.e1.	1.8	12
21	An Update on rFVIIa Use in Females with Rare Bleeding Disorders. Blood, 2019, 134, 1119-1119.	1.4	2
22	Thrombin Generation in Nephrotic Syndrome Is Dependent on Remission Status and Hypercholestrolemia. Blood, 2019, 134, 2422-2422.	1.4	0
23	Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency. Thrombosis and Haemostasis, 2018, 118, 451-460.	3.4	22
24	State of the art in factor XIII laboratory assessment. Transfusion and Apheresis Science, 2018, 57, 700-704.	1.0	21
25	Thrombin-Induced Podocyte Injury Is Protease-Activated Receptor Dependent. Journal of the American Society of Nephrology: JASN, 2017, 28, 2618-2630.	6.1	34
26	Low bleeding rates with increase or maintenance of physical activity in patients treated with recombinant factor <scp>VIII</scp> Fc fusion protein (<scp>rFVIIIF</scp>c) in the Aâ€LONG and Kids Aâ€<scp>LONG</scp> Studies. Haemophilia, 2017, 23, e39-e42.	2.1	10
27	Activated Partial Thromboplastin Time versus Anti-Factor Xa Levels for Monitoring Unfractionated Heparin Therapy in Children: An Institutional Experience. Journal of Pediatric Hematology/Oncology, 2017, 39, 576-577.	0.6	4
28	Developing the First Recombinant Factor XIII for Congenital Factor XIII Deficiency: Clinical Challenges and Successes. Seminars in Thrombosis and Hemostasis, 2017, 43, 059-068.	2.7	15
29	Thrombosis of the Abdominal Veins in Childhood. Frontiers in Pediatrics, 2017, 5, 188.	1.9	14
30	Recombinant factorÂXIII prophylaxis is safe and effective in young children with congenital factor XIIIâ€A deficiency: international phaseÂ3b trial results. Journal of Thrombosis and Haemostasis, 2017, 15, 1601-1606.	3.8	9
31	Validation Study of the Composite Score to Identify Von Willebrand Disease in Children. Journal of Pediatric Hematology/Oncology, 2016, 38, 139-142.	0.6	11
32	BAY 81â€8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial. Haemophilia, 2016, 22, 354-360.	2.1	29
33	Epidemiology of bleeding symptoms and hypermobile Ehlersâ€Danlos syndrome in paediatrics. Haemophilia, 2016, 22, e490-3.	2.1	12
34	Light Transmission Aggregometry Does Not Correlate With the Severity of Î´-Granule Platelet Storage Pool Deficiency. Journal of Pediatric Hematology/Oncology, 2016, 38, 525-528.	0.6	12
35	Reference Range of Platelet Delta Granules in the Pediatric Age Group: An Ultrastructural Study of Platelet Whole Mount Preparations from Healthy Volunteers. Pediatric and Developmental Pathology, 2016, 19, 498-501.	1.0	16
36	The emerging role of coagulation proteases in kidney disease. Nature Reviews Nephrology, 2016, 12, 94-109.	9.6	81

#	Article	IF	Citations
37	A Review of Hormonal Contraception and Venous Thromboembolism in Adolescents. Journal of Pediatric and Adolescent Gynecology, 2016, 29, 402-408.	0.7	6
38	Nephrotic Syndrome Clots Are Resistant to Fibrinolysis Despite Elevated Plasmin Generation. Blood, 2016, 128, 3767-3767.	1.4	1
39	Long-Term Efficacy and Quality of Life with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Prophylaxis in Pediatric, Adolescent, and Adult Subjects with Target Joints and Severe Hemophilia a. Blood, 2016, 128, 3791-3791.	1.4	2
40	Infections Are Associated with Higher Risk of Venous Thromboembolism in Hospitalized Children with Nephrotic Syndrome. Blood, 2016, 128, 3811-3811.	1.4	0
41	Safety and Efficacy of Recombinant Factor XIII (FXIII) in Patients with Congenital FXIII A-Subunit Deficiency, Results from the Mentorâ„¢2 Trial. Blood, 2016, 128, 2573-2573.	1.4	0
42	Development of a pediatric-specific clinical probability tool for diagnosis of venous thromboembolism: a feasibility study. Pediatric Research, 2015, 77, 463-471.	2.3	22
43	Pharmacokinetic characterization of recombinant factor XIII (FXIII)â€A2 across age groups in patients with FXIII Aâ€subunit congenital deficiency. Haemophilia, 2015, 21, 380-385.	2.1	13
44	Disease Severity Correlates with Thrombotic Capacity in Experimental Nephrotic Syndrome. Journal of the American Society of Nephrology: JASN, 2015, 26, 3009-3019.	6.1	23
45	An Orthogonal Array Optimization of Lipid-like Nanoparticles for mRNA Delivery in Vivo. Nano Letters, 2015, 15, 8099-8107.	9.1	182
46	Healthcare burden of venous thromboembolism in childhood chronic renal diseases. Pediatric Nephrology, 2015, 30, 829-837.	1.7	19
47	Crucial role for the VWF A1 domain in binding to type IV collagen. Blood, 2015, 125, 2297-2304.	1.4	88
48	AKI in Children Hospitalized with Nephrotic Syndrome. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 2110-2118.	4.5	87
49	Low Bleeding Rates with Increase or Maintenance of Physical Activity in Patients Treated with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in the A-LONG and Kids A-LONG Studies. Blood, 2015, 126, 3543-3543.	1.4	2
50	Long-Term Efficacy of rFVIIIFc Prophylaxis in Pediatric, Adolescent, and Adult Subjects with Target Joints and Severe Hemophilia A. Blood, 2015, 126, 3520-3520.	1.4	0
51	Pharmacokinetics of recombinant factor XIII at steady state in patients with congenital factor XIII Aâ€subunit deficiency. Journal of Thrombosis and Haemostasis, 2014, 12, 2038-2043.	3.8	21
52	Venous thromboembolism in pediatric nephrotic syndrome. Pediatric Nephrology, 2014, 29, 989-997.	1.7	69
53	Increasing frequency of acute kidney injury amongst children hospitalized with nephrotic syndrome. Pediatric Nephrology, 2014, 29, 139-147.	1.7	37
54	Endogenous Thrombin Potential is Directly Correlated with Proteinuria Severity in Both Nephrotic Syndrome Patients and an Animal Model of Nephrotic Syndrome. Blood, 2014, 124, 4243-4243.	1.4	1

#	Article	IF	Citations
55	Thrombin Induces Apoptosis in Human and Rat Podocytes in a Protease Activated Receptor (PAR)-Dependent Manner. Blood, 2014, 124, 2808-2808.	1.4	0
56	New Data on the Safety and Efficacy of Recombinant FXIII in Patients with Congenital FXIII A-Subunit Deficiency. Blood, 2014, 124, 1520-1520.	1.4	0
57	Thrombin Generation Is Directly Correlated To Proteinuria Severity In An Experimental Model Of Nephrotic Syndrome. Blood, 2013, 122, 3615-3615.	1.4	0
58	Pharmacokinetic Characterisation Of Recombinant FXIII Across Age Groups In Patients With FXIII Subunit A Congenital Deficiency. Blood, 2013, 122, 3613-3613.	1.4	0
59	Epidemiology and Pathophysiology of Nephrotic Syndromeâ€"Associated Thromboembolic Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 513-520.	4.5	256
60	Pediatric venous thromboembolism in the United States: A tertiary care complication of chronic diseases. Pediatric Blood and Cancer, 2012, 59, 258-264.	1.5	155
61	The PFAâ€100^{Â®} does not predict deltaâ€granule platelet storage pool deficiencies. Haemophilia, 2012, 18, 626-629.	2.1	26
62	Current and future management of pediatric venous thromboembolism. American Journal of Hematology, 2012, 87, S68-74.	4.1	47
63	Pulmonary morbidity of catheter-related pediatric venous thromboembolism: Old problem, new worry*. Critical Care Medicine, 2011, 39, 1234-1235.	0.9	0
64	Thrombotic Risk of Recombinant Factor Seven in Pediatric Cardiac Surgery: A Single Institution Experience. Annals of Thoracic Surgery, 2010, 89, 570-576.	1.3	21
65	The PFA-100 Does Not Predict Delta-Granule Platelet Storage Pool Deficiencies. Blood, 2010, 116, 2518-2518.	1.4	0
66	Epidemiology and Risk Factors for Thromboembolic Complications of Childhood Nephrotic Syndrome: A Midwest Pediatric Nephrology Consortium (MWPNC) Study. Journal of Pediatrics, 2009, 155, 105-110.e1.	1.8	120
67	Applying diagnostic criteria for type 1 von Willebrand disease to a pediatric population. Pediatric Blood and Cancer, 2009, 52, 102-107.	1.5	13
68	Prevalence of abnormal bone density of pediatric patients prior to blood or marrow transplant. Pediatric Blood and Cancer, 2009, 53, 675-677.	1.5	9
69	Thrombolysis for pediatric venous thromboembolism: Is it time for a trial?. Pediatric Blood and Cancer, 2009, 53, 920-921.	1.5	4
70	Variability in bleeding phenotype in Amish carriers of haemophilia B with the 31008 Câ†'T mutation. Haemophilia, 2009, 15, 91-100.	2.1	19
71	Bleeding symptoms and laboratory correlation in patients with severe von Willebrand disease. Haemophilia, 2009, 15, 918-925.	2.1	30
72	Desmopressin responsiveness in children with Ehlersâ€Danlos syndrome associated bleeding symptoms. British Journal of Haematology, 2009, 144, 230-233.	2.5	44

#	Article	IF	Citations
73	Pediatric Venous Thromboembolism: Redefining Epidemiology.. Blood, 2009, 114, 5055-5055.	1.4	0
74	Common clinical variables predict warfarin maintenance dose and therapeutic resistance. Journal of Thrombosis and Thrombolysis, 2008, 25, 101-101.	2.1	0
75	Congenital amegakaryocytic thrombocytopenia: The diagnostic importance of combining pathology with molecular genetics. Pediatric Blood and Cancer, 2008, 50, 1263-1265.	1.5	37
76	The Cost of Pediatric Stroke Care and Rehabilitation. Stroke, 2008, 39, 161-165.	2.0	76
77	Social and Ethical Controversies in Thrombophilia Testing and Update on Genetic Risk Factors for Venous Thromboembolism. Seminars in Thrombosis and Hemostasis, 2008, 34, 549-561.	2.7	14
78	Fibrinogen Columbus: a novel gamma Gly200Val mutation causing hypofibrinogenemia in a family with associated thrombophilia. Haematologica, 2007, 92, 1151-1152.	3.5	7
79	Recommendations for Screening for Thrombophilic Tendencies in Teenage Females Prior to Contraceptive Initiation. Journal of Pediatric and Adolescent Gynecology, 2006, 19, 313-316.	0.7	8
80	Hemolytic Anemia in a 5-Year-Old Child. Laboratory Medicine, 2006, 37, 746-748.	1.2	0
81	Temozolomide and Radiation for Aggressive Pediatric Central Nervous System Malignancies. Journal of Pediatric Hematology/Oncology, 2005, 27, 254-258.	0.6	9
82	Factor V Leiden polymorphism modifies sepsis outcome: Evidence from animal studies. Critical Care Medicine, 2004, 32, S233-S238.	0.9	33
83	Cause-effect relation between hyperfibrinogenemia and vascular disease. Blood, 2004, 103, 1728-1734.	1.4	80
84	Concurrent poststreptococcal glomerulonephritis and autoimmune hemolytic anemia. Pediatric Nephrology, 2003, 18, 1301-1303.	1.7	16
85	Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood, 2003, 102, 3085-3092.	1.4	209
86	Characterization of a Mouse Model for Thrombomodulin Deficiency. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1531-1537.	2.4	138